4 stories
MHRA — the UK Medicines and Healthcare products Regulatory Agency — is the European-side counterpart most actively covered on this site. The agency has been visible on research-peptide enforcement, NHS coverage decisions for branded GLP-1s, and the broader UK aesthetic-medicine market.
Recent threads: MHRA warning letters and product seizures targeting peptide vendors selling BPC-157, TB-500, and other research peptides; updates on UK telehealth GLP-1 prescribing; and the agency's coordination with Trading Standards on online sale of unapproved peptides.
Stories here cover MHRA actions, NHS coverage, and UK enforcement. See #uk for the broader UK thread and #uk-regulation for related rule-making.
The UK's MHRA is investigating peptide clinics promoting BPC-157, MOTS-C, and Cortexin with unproven claims. Making medicinal claims classifies these products as medicines under UK law.
The UK's medicines regulator is investigating whether clinics are breaking the law by making unsubstantiated medicinal claims for unregulated peptide therapies.
The MHRA is investigating whether UK peptide clinics are breaking the law by making medicinal claims for unregulated peptides like BPC-157 and Thymosin Alpha. Clinics were found charging £350–£450/month per peptide despite labeling them "research only."
The MHRA told Parliament that 81,000 doses have been seized in three years, with illegal GLP-1 profit margins rivaling class A drugs.